无麸质饮食治疗原发性硬化性胆管炎及其相关结肠炎的前瞻性初步研究
该前瞻性临床初步研究对15例原发性硬化性胆管炎合并炎症性肠病(PSC-IBD)患者实施为期8周的无麸质及无淀粉酶胰蛋白酶抑制剂饮食,主要结局结肠炎症内镜评分和肝硬度均未改变,但黏膜促炎细胞因子及纤维化标志物显著下降,肠道屏障转录组改善,患者瘙痒、疲劳等症状及碱性磷酸酶无显著变化。
要点
- 8周无麸质饮食未改善PSC-IBD患者结肠炎症内镜评分和肝硬度。
- 黏膜促炎细胞因子IL6、IL8、CCL2、TNFα表达显著下调。
- 肝纤维化标志物血小板反应蛋白-2和-4显著下降,肠道屏障转录组改善。
核心结论
- 短期无麸质饮食未使PSC-IBD患者获得临床改善,但可能改善肠道炎症和屏障功能的生物标志物并伴随肠道微生物群变化,需进一步研究其治疗潜力。
研究设计与样本
- 前瞻性临床初步研究,对15例PSC-IBD患者实施为期8周的无麸质及无淀粉酶胰蛋白酶抑制剂饮食。
- 主要结局为经直肠乙状结肠镜评估的结肠炎症和经瞬时弹性成像测量的肝硬度(作为纤维化、炎症和胆汁淤积的替代指标),在饮食前后对比。
主要发现
- 研究未达到主要结局:内镜评分和肝硬度保持不变。
- 黏膜促炎细胞因子和趋化因子如IL6、IL8、CCL2和TNFα表达显著下调。
- 肝纤维化和基质重塑的两个关键标志物血小板反应蛋白-2和-4显著下降。
- 微生物群组成轻微变化,包括病原体Romboutsia ilealis减少,肠道转录组显示肠道屏障改善。
- 瘙痒、疲劳、总体健康状况、粪便钙卫蛋白水平和血清碱性磷酸酶无显著变化。
关键数值与推荐
- 主要结局内镜评分和肝硬度在8周无麸质饮食前后保持不变。
- 黏膜IL6、IL8、CCL2、TNFα表达显著下调。
- 血小板反应蛋白-2和-4显著下降。
- 瘙痒、疲劳、总体健康状况、粪便钙卫蛋白和血清碱性磷酸酶无显著变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive bile duct disease associated with inflammatory bowel disease (PSC-IBD). AIM: To investigate whether patients with PSC-IBD benefit from a gluten-free and amylase trypsin inhibitor (ATI)-free diet (GFD). METHODS: We performed a prospective clinical pilot study administering an eight-week GFD. The primary outcomes were colonic inflammation assessed by proctosigmoidoscopy, and liver stiffness (surrogate for fibrosis, inflammation and cholestasis) measured by transient elastography before and after GFD. Amongst the secondary (exploratory) outcomes were colonic mucosal and serum cytokine/chemokine changes, the intestinal microbiome and transcriptome dynamics, and shifts in serum markers of hepatic fibrogenesis. RESULTS: Fifteen patients with PSC-IBD completed the study. The study did not meet its primary outcome: the endoscopic score and liver stiffness remained unchanged. However, the expression of pro-inflammatory mucosal cytokines and chemokines such as IL6, IL8, CCL2, and TNFα was significantly down-regulated. Two critical markers of liver fibrosis and matrix remodelling, thrombospondin-2 and -4, decreased significantly. The microbiota composition changed slightly, including a decrease in the pathogen Romboutsia ilealis. The intestinal transcriptome indicated a gut barrier improvement. Pruritus, fatigue, overall well-being, faecal calprotectin levels, and serum alkaline phosphatase did not change significantly. CONCLUSIONS: This study did not demonstrate a clinical improvement with short-term GFD in patients with PSC-IBD. However, a gluten/ATI-free diet may improve biomarkers of intestinal inflammation and barrier function in these patients with associated changes in the enteric microbiota. Further investigation of the therapeutic potential of the GFD in PSC-IBD is warranted.
引用
- Liwinski T, Hübener S, Henze L, et al. A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis. Aliment Pharmacol Ther. 2022. PMID: 36266939. doi:10.1111/apt.17256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。